Solana ETF 获批前景:从「几乎无望」到「2025 年底前可期」,当前有哪些挑战?

Takeda

company

About

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company in Japan.

Details

Last Funding Type
Grant
Last Funding Money Raised
$19.80M
Industries
Biotechnology,Health Care,Health Diagnostics,Medical,Pharmaceutical
Founded date
Jun 12, 1781
Number Of Employee
10001 - max
Operating Status
Active
Stock Symbol
tyo:4502
Legal Name
Takeda Pharmaceutical Company Limited
Also Known As
TAP Pharmaceuticals,武田薬品工業
Investor Type
Venture Capital

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company in Japan.

The company markets its original products, such as the anti-prostatic cancer agent leuprolide acetate (marketed as Lupron Depot, Enantone, Prostap, and Leuplin), the anti-peptic ulcer agent lansoprazole (marketed as Prevacid, Ogast, Takepron, and other names), the anti-hypertensive agent candesartan cilexetil (marketed as Blopress, Kenzen, and Amias), and the anti-diabetic agent pioglitazone hydrochloride (marketed as Actos). Segments The company operates its business in two categories, Pharmaceutical business and Other businesses. The Pharmaceutical business represents the ethical drug business and healthcare business.

Other businesses include business activities involving the production and marketing of a range of products, including vitamin bulks, test reagents & clinical diagnostics, photographic chemicals, and inorganic chemicals.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$57.80M
Takeda has raised a total of $57.80M in funding over 2 rounds. Their latest funding was raised on Sep 1, 2016 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 1, 2016 Grant $19.80M Detail
May 8, 2016 Grant $38M 1 Detail
May 14, 1999 IPO Detail

Investments

Number of Investments
Number of Lead Investments
43
13
Takeda has made 43 investments. Their most recent investment was on Apr 19, 2022, when Hedge raised $3.70M.
Date Company Name
Round Money Raised Industry Lead Investor
Apr 19, 2022 Hedge
Seed $3.70M Blockchain
Dec 21, 2021 Ambys Medicines
Series A $47M Biotechnology
Series B $300M Biotechnology
Nov 13, 2020 Bridge Medicines
Series Unknown $10M Pharmaceutical
Seed Biotechnology Yes

Investors

Number of Lead Investors
Number of Investors
1
Takeda is funded by 1 investors. Bill & Melinda Gates Foundation are the most recent investors.
Investor Name Lead Investor Funding Round
Bill & Melinda Gates Foundation Grant

Employee Profiles

Number of Employee Profiles
50
Takeda has 50 current employee profiles, including Employee Andrea Pecci
Employee
Executive
Executive
Executive
Executive

Exits

Takeda has had 10 exits. Takeda most notable exits include Maverick Therapeutics ,   Avidity Biosciences

Date Company Name Exit Type Industry
Mar 9, 2021 Maverick Therapeutics M&A Biotechnology Detail
Jun 11, 2020 Avidity Biosciences IPO Biotechnology Detail
Feb 26, 2020 PvP Biologics M&A Biotechnology Detail
Jun 28, 2017 Mersana Therapeutics IPO Biotechnology Detail
Mar 17, 2017 Molecular Templates IPO Biotechnology Detail

Acquisition

Takeda has acquired 15 organizations. Their most recent acquisition was Syrrx on Feb 7, 2005. They acquired Syrrx for $270M.

Date Company Name
Industry Acquisition Type Price
Feb 7, 2005 Syrrx
Biotechnology acquisition $ 270M Detail
Biotechnology acquisition $ 8.68B Detail
Biotechnology Detail
Jun 24, 2009 IDM Pharma
Biotechnology Detail
May 19, 2011 Nycomed Pharma
Health Care acquisition € 9.60B Detail